GEN vs. DOCU, PATH, ESTC, PCOR, CFLT, DUOL, SPSC, KVYO, BRZE, and SQ
Should you be buying Genesis Healthcare stock or one of its competitors? The main competitors of Genesis Healthcare include DocuSign (DOCU), UiPath (PATH), Elastic (ESTC), Procore Technologies (PCOR), Confluent (CFLT), Duolingo (DUOL), SPS Commerce (SPSC), Klaviyo (KVYO), Braze (BRZE), and Block (SQ). These companies are all part of the "prepackaged software" industry.
DocuSign (NASDAQ:DOCU) and Genesis Healthcare (NYSE:GEN) are both large-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.
Genesis Healthcare received 56 more outperform votes than DocuSign when rated by MarketBeat users. Likewise, 65.73% of users gave Genesis Healthcare an outperform vote while only 59.71% of users gave DocuSign an outperform vote.
77.6% of DocuSign shares are owned by institutional investors. Comparatively, 82.1% of Genesis Healthcare shares are owned by institutional investors. 1.7% of DocuSign shares are owned by company insiders. Comparatively, 3.3% of Genesis Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Genesis Healthcare has a net margin of 17.83% compared to Genesis Healthcare's net margin of 2.68%. DocuSign's return on equity of 155.48% beat Genesis Healthcare's return on equity.
DocuSign has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Genesis Healthcare has higher revenue and earnings than DocuSign. Genesis Healthcare is trading at a lower price-to-earnings ratio than DocuSign, indicating that it is currently the more affordable of the two stocks.
In the previous week, DocuSign had 1 more articles in the media than Genesis Healthcare. MarketBeat recorded 8 mentions for DocuSign and 7 mentions for Genesis Healthcare. Genesis Healthcare's average media sentiment score of 0.33 beat DocuSign's score of 0.00 indicating that DocuSign is being referred to more favorably in the media.
DocuSign presently has a consensus price target of $60.25, indicating a potential upside of 0.06%. Genesis Healthcare has a consensus price target of $25.75, indicating a potential upside of 2.88%. Given DocuSign's stronger consensus rating and higher probable upside, analysts plainly believe Genesis Healthcare is more favorable than DocuSign.
Summary
Genesis Healthcare beats DocuSign on 13 of the 17 factors compared between the two stocks.
Get Genesis Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genesis Healthcare Competitors List
Related Companies and Tools
